Charles River’s Translational Expertise Set To Shine At Neuroscience 2024 Conference

Charles River Laboratories International, Inc. issued a statement indicating that its neuroscience drug discovery team will be presenting 18 scientific posters at the annual meeting being staged by the Society for Neuroscience (SfN) event, generally known as Neuroscience 2024. This global event will bring together some of the world's leading researchers in state-of-the-art facilities which will be held from October 5-9, 2024, in Chicago, IL. The presentations include independent and collaborative work conducted by clients, and will highlight the advancements in the field. 

Antti Nurmi, Ph.D., MSc, General Manager, CNS Pharmacology, Charles River said, “Charles River is committed to changing the course of neuroscience research. We are committed to providing deep translational expertise as a trusted partner for preclinical models, innovative drug discovery, manufacturing, and commercialisation, ultimately driving towards better outcomes for our clients and patients.”

Genetics, pathology, biomarkers, and endpoints are witnessing significant advancement, driving the power of neuroscience drug discovery, which includes small molecules and the latest therapies. Charles River experts will present posters and lead discussions at the conference on the newest innovations in neuroscience research and novel approaches to neurodegenerative diseases.

The highlights of the event include presentations by Malika Bsibsi on topics such as “Establishment and validation of an in vitro co-culture model to study myelination using human iPSC-derived glutamatergic neurons and oligodendrocytes” and “An iPSC derived neuroinflammation in vitro model of neurons and glial cells” on 6th October at 4:00 to 5:00 pm CDT & 7th October 2:00 to 3:00 pm CDT respectively.

Charles River’s scientific experts will review how prominent developments in genetics, pathology, biomarkers, and endpoints within ALS research impact drug discovery for this progressive and irreversible neurodegenerative disease on Monday, October 7, at 10:00 a.m. CDT in Product Theater 2.

Dr. Susanne Back, Senior Manager at CNS Pharmacology, and Dr. Philip Mitchell, Director of Integrated Biology, will discuss challenging topics such as the utilization of cellular and animal models to recreate disease pathology. Moreover, they will also explain how all these models, when combined with translational readouts, can be used to enhance the clinical success of small molecules, gene therapies and antisense oligonucleotides (ASOs). 

Charles River boasts a worldwide team of approximately 200 neuroscientists dedicated to every stage of drug discovery and development, spanning from fundamental research to regulatory approval. Their comprehensive range of services and collaborative approach are essential for uncovering innovative therapies. Since 2018, Charles River has played a pivotal role in supporting 80% of new neuroscience drugs that received approval from the U.S. Food & Drug Administration (FDA).

Charles River’s comprehensive approach to neurodegenerative diseases is highlighted by recent initiatives, including a strategic partnership with CEBINA to advance innovative neuroscience research and integrate Insightec’s low-frequency ultrasound platform for targeted drug delivery to deep brain structures. Furthermore, Logica®, an AI-driven drug discovery solution combining Valo Health’s Opal Computational Platform™ with Charles River’s expertise, has recently partnered with H. Lundbeck A/S to enhance brain disease research.

A complete schedule of Charles River's events at Neuroscience 2024 can be found online. Additionally, experts will be present at “Booth #417”, where visitors can meet and discuss neuroscience research and drug discovery for better experience.